Adult Attention Deficit Hyperactivity Disorder Clinical Trial
Official title:
A Randomized, Double Blind, Parallel Group, Multicenter Efficacy and Safety Study of SEP-225289 Versus Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
A Phase 2 study of SEP-225289 in adults with attention deficit hyperactivity disorder (ADHD).
This is a Phase 2, randomized, double-blind, parallel-group, multicenter, outpatient study evaluating the efficacy and safety of SEP 225289 in adults with ADHD using 2 oral dosages (4 or 8 mg SEP 225289 once daily [QD]) versus placebo over a 4 week treatment period. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06000501 -
Duration and Efficacy of Azstarys on Adult ADHD Symptoms and Executive Function in Early Evening
|
Phase 4 | |
| Completed |
NCT03721588 -
Clinical and Suicidal Features of Urban, Turkish Middle Age Depressive Patients With Comorbid ADHD
|
||
| Completed |
NCT03324581 -
The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder
|
Phase 2 | |
| Active, not recruiting |
NCT06221930 -
Researching the Effectiveness of Attexis, a Digital Health Application for Adults With Attention Deficit Hyperactivity Disorder
|
N/A | |
| Completed |
NCT02160262 -
Open-label Safety Study in Adults With ADHD
|
Phase 3 | |
| Completed |
NCT02276209 -
Dasotraline Adult ADHD Study
|
Phase 3 | |
| Completed |
NCT01798381 -
Essential Fatty Acids in Adult ADHD
|
Phase 3 | |
| Completed |
NCT00553319 -
Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence
|
Phase 2/Phase 3 |